PATH-48. RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY. (12th November 2021)

• Record Type: Journal Article
• Authors: Patel, Areeba; Dogan, Helin; Payne, Alexander; Sievers, Philipp; Schoebe, Natalie; Schrimpf, Daniel; Stichel, Damian; Holmes, Nadine; Euskirchen, Philipp; Hench, Jürgen; Frank, Stephan; Rosenstiel-Goidts, Violaine; Dieterich, Christoph; Herold-Mende, Christel; Pfister, Stefan; Wick, Wolfgang; Schlesner, Matthias; Loose, Matthew; Jones, David; von Deimling, Andreas; Sill, Martin; Sahm, Felix
• Is Part Of: Neuro-oncology. Volume 23: Supplement 6(2021)
• Page Start: vi126
• Page End: vi126
• Publication Date: 2021-11-12
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab196.500
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: The WHO classification 2021 includes multiple molecular markers for routine diagnostics in addition to histology. Sequencing setup for complete molecular profiling requires considerable investment, while batching samples for sequencing and methylation profiling can delay turnaround time. We introduce RAPID-CNS 2, a nanopore adaptive sequencing pipeline that enables comprehensive mutational, methylation and copy number profiling of CNS tumours with a single third generation sequencing assay. It can be run for single samples and offers highly flexible target selection requiring no additional library preparation. METHODS: Utilising ReadFish, a toolkit enabling targeted nanopore sequencing, we sequenced DNA from 22 diffuse glioma patient samples on a MinION device. Target regions comprised our Heidelberg brain tumour NGS panel and pre-selected CpG sites for methylation classification by an adapted random forest classifier. Pathognomonic alterations, copy number profiles, and methylation classes were called using a custom bioinformatics pipeline. Results were compared to their corresponding NGS panel-seq and EPIC array outputs. RESULTS: Complete concordance with the EPIC array was found for copy number profiles from RAPID-CNS 2 . 94% pathognomonic mutations were congruent with NGS panel-seq. MGMT promoter status was correctly identified in all samples. Methylation families were detected with 96% congruence. Among the alterations decisive for rendering a classification-compatible integrated diagnosis, 97% of the alterations were consistent over the entire cohort (completely congruent in 19/22 cases and sufficient for unequivocal diagnosis in all). CONCLUSIONS: RAPID-CNS 2 provides a swift and highly flexible alternative to conventional NGS and array- based methods for SNV/Indel analysis, detection of copy number alterations and methylation classification. The turnaround time of ~4 days can be further shortened to < 12h by altering target sizes. It offers a low-capital approach that would be cost-efficient for low throughput settings and invaluable in cases requiring immediate diagnoses.